HomeAI · summaries
Storia in 6 fonti
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
GSK lung cancer drug gets speedy approval following $10.6B deal
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
- ·
medpagetoday.com
FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer
Zidesamtinib is indicated for patients who received a prior ROS1 inhibitor
